New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
13:09 EDTCAH, NAVBFDA approves Navidea Lymphoseek injection for use in lymphatic mapping
Navidea Biopharmaceuticals (NAVB) announced U.S. Food and Drug Administration approval of Lymphoseek Injection, a novel product indicated for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek will be sold and distributed in the U.S. on an exclusive basis by Cardinal Health (CAH).
News For NAVB;CAH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:34 EDTNAVBNavidea reiterates FY15 Lymphoseek product revenue view $10M-$12M
Subscribe for More Information
07:34 EDTNAVBNavidea reports Q2 EPS (6c), two estimates (4c)
Subscribe for More Information
07:08 EDTCAHCardinal Health reports Q4 Pharmaceutical revenue up 23% to $24.7B
Subscribe for More Information
07:08 EDTCAHCardinal Health raises FY16 non-GAAP EPS to $4.85-$5.05 from $4.28-$4.38
FY16 EPS consensus of $4.37. The updated guidance is due to strong FY15 performance momentum it carried into FY16. It expects financial performance to be weighted towards 2H16.
07:08 EDTCAHCardinal Health reports Q4 non-GAAP EPS $1.00, consensus 99c
Subscribe for More Information
July 29, 2015
15:08 EDTCAHNotable companies reporting before tomorrow's open
Subscribe for More Information
07:32 EDTNAVBNavidea wins $1.7M fast track NIH SBIR grant for evaluation of RA treatment
Subscribe for More Information
July 28, 2015
07:35 EDTNAVBNavidea, MGH to evaluate Manocept for detection of cardiovascular disease
Subscribe for More Information
July 23, 2015
08:50 EDTNAVBNavidea announces peer-reviewed publication of data on Lymphoseek
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use